Scarica l'app Stockscreener
2.77
1.77%
-0.05
Dopo l'orario di chiusura:
2.78
0.010
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.82
Aprire:
$2.81
Volume 24 ore:
3.81M
Relative Volume:
0.77
Capitalizzazione di mercato:
$853.44M
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
55.40
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+6.13%
1M Prestazione:
-51.06%
6M Prestazione:
-50.27%
1 anno Prestazione:
-46.21%
Intervallo 1D:
$2.70
$2.81
Intervallo di 1 settimana:
$2.5215
$2.92
Portata 52W:
$2.5215
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.77 | 853.44M | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind Corp Stock (ISIN: US5638651064) Faces Pressure Amid Biotech Selloff and Analyst Cuts - AD HOC NEWS
MannKind (NASDAQ:MNKD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Why MannKind Needs Your Attention - RTTNews
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's Why - MarketBeat
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - The Manila Times
MannKind presents Afrezza data at diabetes conference - Investing.com
MannKind Corporation to Present Data on Inhaled Insulin Afrezza at ATTD 2026 Conference - Quiver Quantitative
Afrezza needle-free insulin for kids heads for FDA decision May 29, 2026 - Stock Titan
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind settles $36.3M convertible notes with cash, shares By Investing.com - Investing.com Canada
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Re - GuruFocus
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
MannKind closes note deal with $35.5M cash and 569,023 shares - Stock Titan
Wedbush Lowers Price Target for MannKind (MNKD) While Maintainin - GuruFocus
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wedbush - MarketBeat
MannKind Announces Settlement of Convertible Senior Notes - Yahoo Finance
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Finviz
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
MannKind (NASDAQ:MNKD) Sets New 1-Year LowHere's What Happened - MarketBeat
MannKind (NASDAQ: MNKD) CFO adds 5,000 shares via stock purchase plan - Stock Titan
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan - Stock Titan
MannKind (MNKD) director reports vesting of 45,025 performance-based stock options - Stock Titan
MannKind (MNKD) CEO gains stock and option vesting on milestones - Stock Titan
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade - MarketBeat
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook By Investing.com - Investing.com Canada
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook - Investing.com
RBC Capital downgrades MannKind stock rating on royalty concerns By Investing.com - Investing.com Canada
RBC Capital downgrades MannKind stock rating on royalty concerns - Investing.com
A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns - simplywall.st
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MannKind Corp. Hits Day Low at $2.94 Amid Price Pressure - Markets Mojo
MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance - Markets Mojo
MannKind Corporation (MNKD): A Bull Case Theory - Finviz
MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About MannKind Corp (MNKD) - GuruFocus
MNKD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5 - GuruFocus
What's Going On With MannKind Stock Friday? - Benzinga
Wells Fargo Lowers MNKD Price Target to $7.00, Maintains Overwei - GuruFocus
MNKD: HC Wainwright & Co. Lowers Price Target to $8.00 | MNKD St - GuruFocus
Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance
Why MannKind Stock Tumbled on Thursday - Yahoo Finance
MannKind at Oppenheimer Conference: Strategic Insights for 2026 - Investing.com
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Earnings call transcript: MannKind Q4 2025 results show mixed performance By Investing.com - Investing.com South Africa
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):